Advanced Gastrointestinal Stromal Tumors (GISTs) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Advanced Gastrointestinal Stromal Tumors (GISTs) Market Outlook

Thelansis’s “Advanced Gastrointestinal Stromal Tumors (GISTs) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Advanced Gastrointestinal Stromal Tumors treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Advanced Gastrointestinal Stromal Tumors (GISTs) Overview

Gastrointestinal stromal tumors (GISTs) represent 0.1–0.3% of gastrointestinal malignant neoplasms and are primarily located within the mesenchymal tissue of the gastrointestinal tract. These tumors can manifest at any age, with a median patient age of 60–65 years. Clinically, GISTs often present with symptoms such as gastrointestinal bleeding, anemia, and abdominal pain. The stomach is the most common site of occurrence, accounting for approximately 50–60% of cases, followed by the small intestine (20–30%) and, less frequently, the colon and rectum (5%) and the esophagus (<1%). Metastatic disease is identified in approximately 15% of patients at diagnosis. Before the advent of targeted therapies, the management of GISTs was challenging due to their poor response to conventional chemotherapy and radiation, making surgical resection the primary therapeutic option. However, many patients who initially undergo surgery for GISTs eventually experience disease recurrence. Historically, the prognosis for patients with advanced GISTs has been poor, with limited effective treatment options available. Significant progress was made with the approval of ripretinib by the Food and Drug Administration (FDA) on May 15, 2020. This drug is indicated for adult patients with advanced GISTs who have previously been treated with three or more kinase inhibitors, including imatinib.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: